Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization

Basit Öğe Kaydı
dc.authoridCoban-Karatas, Muge/0000-0002-7903-5075
dc.authoridyuce sezen, aslihan/0000-0003-3902-4520
dc.authoridsariturk, cagla/0000-0002-4130-1059
dc.contributor.authorKaratas, Muge Coban
dc.contributor.authorYilmaz, Gursel
dc.contributor.authorSezen, Aslihan Yuce
dc.contributor.authorSariturk, Cagla
dc.date.accessioned2024-11-07T13:32:45Z
dc.date.available2024-11-07T13:32:45Z
dc.date.issued2022
dc.departmentNiğde Ömer Halisdemir Üniversitesi
dc.description.abstractObjectives: To compare best corrected visual acuity (BCVA), central macular thickness (CMT), and central choroidal thickness (CCT) in patients with type 2 macular telangiectasia (MacTel 2) and a control group and to evaluate the efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in MacTel 2 patients with macular neovascularization (MNV). Materials and Methods: We conducted a retrospective chart review of consecutive MacTel 2 patients who underwent a full ophthalmologic examination including BCVA and dilated fundus examination with slit-lamp biomicroscopy, fluorescein angiography, and optical coherence tomography imaging at baseline and follow-up visits. BCVA, CMT, and CCT were compared between all identified patients (n=26) and a control group (n=30). A subgroup analysis was performed among eyes with MNV (n=7) before and after treatment. Results: CMT and CCT were significantly lower in the MacTel 2 group compared to the control group. Forty-one treatment-naive eyes without MNV proliferation showed no significant change in BCVA, CMT, or CCT during follow-up. Eight eyes of 7 MacTel 2 patients developed MNV during follow-up. All of the patients were treated with intravitreal anti-VEGF. Conclusion: It is important to closely follow MacTel 2 patients for MNV development. To avoid adverse effects, we prefer to monitor patients who have not yet developed MNV. Patients with proliferative MacTel 2 with decreasing visual function may benefit from intravitreal anti-VEGF treatment.
dc.identifier.doi10.4274/tjo.galenos.2021.75608
dc.identifier.endpage49
dc.identifier.issn1300-0659
dc.identifier.issn2147-2661
dc.identifier.issue1
dc.identifier.pmid35196839
dc.identifier.scopus2-s2.0-85125215186
dc.identifier.scopusqualityN/A
dc.identifier.startpage45
dc.identifier.trdizinid1171997
dc.identifier.urihttps://doi.org/10.4274/tjo.galenos.2021.75608
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1171997
dc.identifier.urihttps://hdl.handle.net/11480/15580
dc.identifier.volume52
dc.identifier.wosWOS:000761159800008
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Ophthalmological Soc
dc.relation.ispartofTurk Oftalmoloji Dergisi-Turkish Journal of Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241106
dc.subjectMacular telangiectasia
dc.subjectmacular neovascularization
dc.subjectanti-VEGF treatment
dc.titleClinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu